Navigant, Lumere Collaborate to Help Healthcare Providers Target Clinical and Financial Variation

Navigant (NYSE: NCI) and Lumere today announced a collaboration to help healthcare providers implement evidence-based, technology-enabled consulting solutions aimed at reducing clinical and financial variation. The goal of the collaboration is to assist hospitals and health systems with reducing unnecessary utilization of drugs and medical devices in such areas as orthopedic, spine, cardiac, and surgical services.

Research suggests up to a quarter of overall healthcare expenditures are wasteful and not associated with improved quality. A proven way to reduce waste is to target unnecessary variation in clinical processes. However, providers often lack the resources to analyze major clinical cost factors necessary to drive action.

“For providers, the focus on reducing unwarranted utilization has only intensified as operating margins dwindle and the pressure to reduce costs while maintaining quality rises,” said Dave Zito, managing director and Navigant’s Healthcare segment leader. “We believe the combination of Lumere’s research and analytics capabilities, and Navigant’s proven successes working with providers nationwide, creates a unique clinical supply chain solution that can drive sustainable quality and financial improvements.”

By providing both physicians and hospital leaders with clinically derived, evidence-based data, Lumere accelerates their ability to reduce unnecessary and costly clinical variation.

“We’re honored to collaborate with Navigant to help enable evidence-based medicine that delivers clear clinical and financial benefits,” said Hani Elias, JD, MPH, Lumere co-founder and CEO. “In our experience, physicians are hungry for data that will help them make decisions that are both patient-focused and cost-effective. Our technology not only helps illuminate new opportunities, but also provides caregivers data they’ve long sought to make informed decisions.”

By leveraging Lumere’s solutions both during and after Navigant engagements, providers may also be better equipped to better:

• Understand cost-reduction opportunities that are based on utilization and unwarranted variation.
• Engage physicians around opportunities to standardize to drugs and devices that demonstrate clinically equivalent outcomes at a lower cost.
• Optimize the type and frequency of products used based on specific patient circumstances and cases.
• Improve the rigor of cost-management programs, such as value analysis.

A Navigant analysis suggests U.S. hospitals could reduce their supply chain expenses by 18% without affecting quality.

Navigant’s Healthcare supply chain practice works with hospitals and health systems nationwide to streamline clinical care pathways while lowering the associated cost of treatment and creating an environment that empowers those supporting it.

About Navigant

Navigant Consulting, Inc. (NYSE: NCI) is a specialized, global professional services firm that helps clients take control of their future. Navigant’s professionals apply deep industry knowledge, substantive technical expertise, and an enterprising approach to help clients build, manage, and/or protect their business interests. With a focus on markets and clients facing transformational change and significant regulatory or legal pressures, the firm primarily serves clients in the healthcare, energy, and financial services industries. Across a range of advisory, consulting, outsourcing, and technology/analytics services, Navigant’s practitioners bring sharp insight that pinpoints opportunities and delivers powerful results. More information about Navigant can be found at navigant.com.

About Lumere

Lumere is at the forefront of clinical decision making for drugs and devices, offering evidence-based solutions and services for all providers that improve care and reduce cost across the patient journey. For more information, visit lumere.com, find us on LinkedIn, follow @LumereHQ on Twitter and like us on Facebook.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180523005220/en/

Navigant Investor Relations
Kyle Bland
312.573.5624
[email protected]
or
Lumere
Pam Flores
773.218.9260
[email protected]
or
Navigant
Alven Weil
704.995.5607
[email protected]